Key result
Leadless pacemakers show no significant difference in complication risk versus transvenous pacemakers.
Why the study?
Leadless pacemakers were designed as an alternative to transvenous systems to avoid transvenous complications, but their pooled safety and efficacy required systematic review.
Does a leadless pacemaker reduce adverse events compared to a transvenous pacemaker in patients requiring single chamber ventricular pacing?
Meta-Analysis (n=2,496)
Does a leadless pacemaker reduce adverse events compared to a transvenous pacemaker in patients requiring single chamber ventricular pacing?
Leadless pacemakers are safe and effective for single chamber ventricular pacing, with complication rates comparable to traditional transvenous pacemakers.
Answers are grounded in this paper and cite their sources.
Supports the safety of leadless pacing as a viable alternative to transvenous systems; confirms.
BACKGROUND: Leadless pacemakers have been designed as an alternative to transvenous systems which avoid some of the complications associated with transvenous devices. We aim to perform a systematic review of the literature to report the safety and efficacy findings of leadless pacemakers. METHODS: We searched MEDLINE and EMBASE to identify studies reporting the safety, efficacy and outcomes of patients implanted with a leadless pacemaker. The pooled rate of adverse events was determined and random-effects meta-analysis was performed to compare rates of adverse outcomes for leadless compared to transvenous pacemakers. RESULTS: A total of 18 studies were included with 2496 patients implanted with a leadless pacemaker and success rates range between 95.5 and 100%. The device or procedure related death rate was 0.3% while any complication and pericardial tamponade occurred in 3.1% and 1.4% of patients, respectively. Other complications such as pericardial effusion, device dislodgement, device revision, device malfunction, access site complications and infection occurred in less than 1% of patients. Meta-analysis of four studies suggests that there was no difference in hematoma (RR 0.67 95%CI 0.21-2.18, 3 studies), pericardial effusion (RR 0.59 95%CI 0.15-2.25, 3 studies), device dislocation (RR 0.33 95%CI 0.06-1.74, 3 studies), any complication (RR 0.44 95%CI 0.17-1.09, 4 studies) and death (RR 0.45 95%CI 0.15-1.35, 2 studies) comparing patients who received leadless and transvenous pacemakers. CONCLUSION: Leadless pacemakers are safe and effective for patients who have an indication for single chamber ventricular pacing and the findings appear to be comparable to transvenous pacemakers.
No takes yet. Share an insight, caveat, or question.
Darlington et al. (2021) conducted a meta-analysis in Indication for single chamber ventricular pacing (n=2,496). Leadless pacemaker vs. Transvenous pacemaker was evaluated on Any complication (RR 0.44, 95% CI 0.17-1.09). Leadless pacemakers showed no significant difference in the risk of any complication compared to transvenous pacemakers.
Synapse has enriched 10 related papers. Consider them for comparative context: